Evidence map›Paper›PMID 38123559›Full record

ArticleBlood cancer journal2023

Sociodemographic associations with uptake of novel therapies for acute myeloid leukemia.

Andrew Hantel, Colin Cernik, Hajime Uno, Thomas P Walsh, Gregory S Calip, Daniel J DeAngelo, Christopher S Lathan, Gregory A Abel

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Andrew HantelDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0001-9612-3643
Colin CernikDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Hajime UnoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Thomas P WalshDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Gregory S CalipFlatiron Health, New York, NY, USA.ORCID 0000-0002-7744-3518
Daniel J DeAngeloDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0001-7865-2306
Christopher S LathanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Gregory A AbelDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. gregory_abel@dfci.harvard.edu.ORCID 0000-0003-1100-2813
Harvard University · USDana-Farber Cancer Institute · USUniversity of Southern California · US

Funding

Diversifying Acute Leukemia Clinical Trial Enrollment Through Multilevel InterventionK08CA273043 · NCI · DANA-FARBER CANCER INST · PI Andrew Hantel · 2022 to 2026
$1.2M
NCI NIH HHS K08 CA273043
6 · The paper itself

Abstract

Inequitable uptake of novel therapies (NT) in non-cancer settings are known for patients with lower socioeconomic status (SES), People of Color (POC), and older adults. NT uptake equity in acute myeloid leukemia (AML) is not well known. We performed a retrospective cohort study (1/2014-8/2022) of the United States nationwide Flatiron Health

Indexed as

Leukemia, Myeloid, AcuteAgedBridged Bicyclo Compounds, HeterocyclicHumansRetrospective StudiesSulfonamidesBridged Bicyclo Compounds, HeterocyclicSulfonamidesvenetoclax

Identifiers

PMID38123559
PMCPMC10733304
OpenAlexW4390030449

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.